Registration Options

Activity Dates: 10/06/2022 - 07/06/2023

Members can access this product for only $150. Log in or Join now!

Target Audience

This activity serves as an educational tool for pharmacists seeking Board Certified Psychiatric Pharmacist (BCPP) Recertification credit and other pharmacists and health care providers seeking advanced education in patient management, disease state management, information management, and health policy and practice management in the field of psychiatric pharmacy.

Content

The CPNP Substance Use Disorder (SUD) Summit content is intended to improve your ability to care for patients with substance use disorder(s) and mental illness. The SUD Summit offers 10 hours of ACPE- and BCPP- approved programming focused on the complicated relationships between substance use disorders and mental illness. The goal of the Summit is for participants to leave with knowledge and tools to apply in their practice setting as they provide care to those living with substance use and mental health disorders.

The curriculum includes:

  • Online access to the recorded speakers' audio presentations synchronized with their slide presentations (presented live during the Virtual SUD Summit, October 6-7, 2022).
  • For pharmacists, 10 hours of ACPE credit and 10 hours of BCPP Recertification credit achieved by successfully completing the online CPNP recertification examination.
  • Access to the CPNP testing center with exam submission due on or before July 6, 2023.

The CPNP Summit 2022 is an application-based continuing pharmacy education (CPE) activity designed to improve competency of partcipants. An application-based CPE activity requires that participants apply the information learned. In an application-based CPE activity, the learning objectives are written at a higher level in order to assess the learners’ ability to use the information that is learned at the current level of practice by Board Certified Psychiatric Pharmacists. The examination for this product often features case studies requiring that the participant apply the principles learned through the readings.

Course Requirements

To satisfactorily complete the Summit and receive 10 hours of BCPP Recertification and ACPE credit, candidates must meet the following requirements:

  1. Abide by a confidentiality and honesty statement requiring individual completion of the Recertification education.
  2. Complete an online assessment on or before the deadline of July 6, 2023.
  3. Meet the minimum passing score to be determined by a panel of experts within four (4) weeks following the exam deadline.
  4. Completion of an activity evaluation form.
  5. Partial credit is not available for individual topics within the programming; it is either all 10 hours of credit or none.

You will proceed through the following steps to satisfactorily complete this course:

  • Sign in (or create a FREE account).
  • Register for this course.
  • Complete the pre-test before starting the activity.
  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date.
  • Complete the evaluation at the end of the activity.
  • Wait for the official review of exam questions within 4 weeks following the closing date.
  • Receive a passing grade (70%).
  • Provide the necessary details in your profile to ensure correct reporting by CPNP to CPE Monitor.

Participants successfully passing the required assessment/examination will obtain both ACPE and BCPP recertification credit. Credit is awarded in the calendar year the assessment is completed. ACPE credit is reported through CPE Monitor within days of examination submission, while BCPP recertification credit is reported to BPS within 6 weeks after the examination deadline.

Faculty Information and Disclosures

Frederick S. Barrett, PhD
Jacqueline Byrd, PharmD, BCPS, AAHIVP
Phillip Coffin, MD, MIA, VACP, FIDCA
Michelle Colvard, PharmD, BCPP
David Dadiomov, PharmD, BCPP
Kari Franson, PharmD, PhD, BCPP
Danielle Stutzman, PharmD, BCPP
Kristina Ward, PharmD, BCPS, BCPP

View biographical information and disclosures

Learning Objectives

Topic

A New Wave of Cannabis Concerns: The Potential Sequelae of Chronic Cannabis Use
ACPE #: 0284-0000-22-070-L01-P (Application)
Speaker: Kari Franson, PharmD, PhD, BCPP

Learning Objectives:

  1. Illustrate the risk of marijuana use, change in potency, and routes of administration on developing of Cannabis use disorder and other psychiatric disorders.
  2. Evaluate the evidence for managing Cannabis use disorder, Cannabis withdrawal, and cannabinoid hyperemesis syndrome.
  3. Construct management plans for cannabis use disorder, cannabinoid hyperemesis syndrome, and Cannabis withdrawal.
 

Why Do I Need to Taper? Challenges and Evidence Behind Benzodiazepine Discontinuation 
ACPE #
: 0284-0000-22-071-L01-P (Application)
Speaker: Kristina Ward, PharmD, BCPS, BCPP

Learning Objectives:

  1. Identify adverse events secondary to chronic benzodiazepine use.
  2. Recommend evidence-based non-pharmacologic and pharmacologic strategies for addressing barriers to successful tapering of benzodiazepines.
  3. Design a benzodiazepine tapering protocol based on patient-specific characteristics that minimizes withdrawal symptoms.
 

Pre-exposure Prophylaxis (PrEP) for HIV in Persons Who Inject Drugs 
ACPE #
: 0284-0000-22-072-L04-P (Application)
Speaker: Jacqueline Byrd, PharmD, BCPS, AAHIVP

Learning Objectives:

  1. Assess a patient for risk of HIV acquisition through injection practices.
  2. Evaluate evidence supporting PrEP prescribing in persons who inject drugs (PWID).
  3. Implement guideline-driven PrEP-prescribing principles about treatment initiation and appropriate monitoring principles in PWID.
 

The Revolving Door: Improving Transitions of Care for Incarcerated Persons with Opioid Use Disorder 
ACPE #: 0284-0000-22-073-L08-P (Application)
Speaker: David Dadiomov, PharmD, BCPP

Learning Objectives:

  1. Analyze barriers to provide medications for opioid use disorder (MOUD) and consequences of the lack of access to care at time of release from incarceration.
  2. Evaluate the literature regarding role of subcutaneous buprenorphine and long-acting naltrexone before transition back into the community.
  3. Construct a pharmacotherapy plan for MOUD at time of transition from incarceration back into the community.
 

Therapeutic Uses of Psychedelics
ACPE #: 0284-0000-22-074-L01-P (Application)
Speaker: Frederick S. Barrett, PhD

Learning Objectives:

  1. Assess patients who may benefit from psychedelic compounds to treat their psychiatric or substance use disorder.
  2. Implement best practices regarding treatment initiation and appropriate monitoring in persons with psychiatric or substance use disorders.
  3. Evaluate evidence supporting psychedelic therapy in persons with psychiatric and substance use disorders.
 

A Case-Based Approach to Managing the Complexities of Co-Occurring OUD and AUD
ACPE #: 0284-0000-22-075-L08-P (Application)
Speaker: Michelle Colvard, RPH, PharmD, BCPP

Learning Objectives:

  1. Describe the clinical considerations for co-occurring opioid and alcohol use disorders.
  2. Evaluate the evidence for treatment of co-occurring opioid and alcohol use disorders.
  3. Develop a treatment plan for a patient scenario with co-occurring opioid and alcohol use disorders.
 

A Stimulating Discussion on Stimulant Use Disorder
ACPE #: 0284-0000-22-076-L01-P (Application)
Speaker: Phillip Coffin, MD, MIA, FACP, FIDSA

Learning Objectives:

  1. Explain the prevalence and consequences of stimulant misuse and stimulant use disorders in the United States.
  2. Evaluate the evidence supporting pharmacotherapies for stimulant use disorders.
  3. Provide patient education and harm reduction strategies to prevent long-term consequences of stimulant use disorder.
 

Recognizing and Managing Co-occurring Substance Use and Eating Disorders
ACPE #: 0284-0000-22-077-L01-P (Application)
Speaker: Danielle Stutzman, PharmD, BCPP

Learning Objectives:

  1. Illustrate the prevalence and overlapping risk factors for co-occurring substance use disorders and eating disorders.
  2. Categorize the risks of substances most frequently misused in persons with eating disorder.
  3. Choose treatment strategies (non-pharmacologic and pharmacotherapy) for a patient with co-occurring eating disorder and substance use disorder.

 

Continuing Education Credit and Disclosures

Activity Dates: 10/06/2022 - 07/06/2023
ACPE Contact Hours: 10
ACPE Numbers: 0284-0000-22-070-H01-P (Application), 0284-0000-22-071-H01-P (Application), 0284-0000-22-072-H04-P (Application), 0284-0000-22-073-H08-P (Application), 0284-0000-22-074-H01-P (Application), 0284-0000-22-075-H08-P (Application), 0284-0000-22-076-H01-P (Application), 0284-0000-22-077-H01-P (Application)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Pharmacists can obtain 10 hours of ACPE credit and 10 hours of BCPP Recertification credit by successfully completing the online examination.

The College of Psychiatric and Neurologic Pharmacists is approved as a Professional Development Provider for the Board Certified Psychiatric Pharmacist (BCPP) specialty by the Board of Pharmacy Specialties (BPS). (Applicable to programs where individual sessions are listed on separate course pages). This course is part of a 10 hour BCPP recertification product earned after successful completion of the associated BCPP recertification examination for the full product.

25 Years!